Abstract
Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high-dose interleukin 2 (aldesleukin, IL-2) in a 2-year-old child with metastatic melanoma and describes our approach for the administration of this agent to young patients.
(c) 2009 Wiley-Liss, Inc.
MeSH terms
-
Analgesics / administration & dosage
-
Analgesics / therapeutic use
-
Anemia / chemically induced
-
Antidiarrheals / administration & dosage
-
Antidiarrheals / therapeutic use
-
Antiemetics / administration & dosage
-
Antiemetics / therapeutic use
-
Chest Pain / chemically induced
-
Combined Modality Therapy
-
Fatal Outcome
-
Female
-
Fluid Therapy
-
Humans
-
Hypotension / chemically induced
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use*
-
Infant
-
Infusions, Intravenous
-
Interferons / therapeutic use*
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / adverse effects
-
Interleukin-2 / therapeutic use*
-
Lymph Node Excision
-
Lymphatic Metastasis*
-
Melanoma / drug therapy
-
Melanoma / secondary*
-
Melanoma / surgery
-
Neoplasm Recurrence, Local / drug therapy*
-
Premedication
-
Pulmonary Edema / chemically induced
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / surgery
Substances
-
Analgesics
-
Antidiarrheals
-
Antiemetics
-
Immunologic Factors
-
Interleukin-2
-
Interferons